A pilot open-label trial of minocycline in patients with autism and regressive features

Journal of Neurodevelopmental Disorders

Susan E Swedo³  David M Neville³  Arun Azhagiri¹  Li-Ching Lee²  Audrey Thurm³  Ashura Buckley³  Carlos A Pardo¹ 

[1] Department of Neurology, Pathology 627, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA;Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Room E6032, Baltimore, MD, 21205, USA;Pediatrics & Developmental Neuroscience Branch, National Institute of Mental Health, 10 Center Drive, Bldg 10/RM 1C250/MSC 1255, Bethesda, MD, 20892, USA

关键词: BDNF;    Neurotrophins;    Metalloproteinases;    Chemokines;    Cytokines;    Clinical trial;    Neuroinflammation;    Microglia;    Minocycline;    Autism;   

Others  :  811327
DOI  :  10.1186/1866-1955-5-9

 received in 2012-11-27, accepted in 2013-03-20,  发布年份 2013

【 摘 要 】

Background

Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression.

Methods

Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation.

Results

Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and α-2 macroglobulin (α-2 M), was also significantly lower (P = 0.028) while the mature BDNF/α-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-α, CD40L, IL-6, IFN-γ and IL-1β when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline.

Conclusions

Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration.

Trial registration

NCT00409747

【 授权许可】

   
2013 Pardo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Rapin I: Autism. N Engl J Med 1997, 337:97-104.
• [2]Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de WJ: Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011, 25:40-45.
• [3]Ozonoff S, Iosif AM, Baguio F, Cook IC, Hill MM, Hutman T, Rogers SJ, Rozga A, Sangha S, Sigman M, Steinfeld MB, Young GS: A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry 2010, 49:256-266.
• [4]Laurence JA, Fatemi SH: Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 2005, 4:206-210.
• [5]Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, Ji L, Brown T, Malik M: Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009, 207:111-116.
• [6]Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, Courchesne E, Everall IP: Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010, 68:368-376.
• [7]Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA: Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67-81.
• [8]Ransohoff RM: Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009, 31:711-721.
• [9]Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A: The role of microglia in the healthy brain. J Neurosci 2011, 31:16064-16069.
• [10]Kettenmann H, Hanisch UK, Noda M, Verkhratsky A: Physiology of microglia. Physiol Rev 2011, 91:461-553.
• [11]Sierra A, Encinas JM, Deudero JJ, Chnacey JH, Enikolopov G, Overstreet-Wadiche LS, Tsirka SE, Maletic-Savatic M: Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 2010, 7:483-495.
• [12]Derecki NC, Cronk JC, Kipnis J: The role of microglia in brain maintanance: Implications for Rett syndrome. Trends Immunol 2013, 34:144-150.
• [13]Amaral DG, Schumann CM, Nordahl CW: Neuroanatomy of autism. Trends Neurosci 2008, 31:137-145.
• [14]Alano CC, Kauppinen TM, Valls AV, Swanson RA: Minocycline inhibits poly (ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006, 103:9685-9690.
• [15]Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M: Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004, 17:359-366.
• [16]Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, Mendoza M, Mass J, Kushner G, Miller RG: Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004, 62:1845-1847.
• [17]Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, Macarthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R, Western ALS Study Group: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
• [18]Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res 2009, 196:168-179.
• [19]Nutile-McMenemy N, Elfenbein A, Deleo JA: Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv1.3 channel expression. J Neurochem 2007, 103:2035-2046.
• [20]Plane JM, Shen Y, Pleasure DE, Deng W: Prospects for minocycline neuroprotection. Arch Neurol 2010, 67:1442-1448.
• [21]Orsucci D, Calsolaro V, Mancuso M, Siciliano G: Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 2009, 8:222-231.
• [22]Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: The promise of minocycline in neurology. Lancet Neurol 2004, 3:744-751.
• [23]Plane JM, Liu R, Wang TW, Silverstein FS, Parent JM: Neonatal hypoxic-ischemic injury increases forebrain subventricular zone neurogenesis in the mouse. Neurobiol Dis 2004, 16:585-595.
• [24]Hinwood M, Morandini J, Day TA, Walker FR: Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex 2012, 22:1442-1454.
• [25]Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, Patten SB, Duquette P, Antel JP, Mitchell JR: Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004, 55:756.
• [26]Galpern WR, Singhal AB: Neuroprotection: lessons from a spectrum of neurological disorders. Int J Stroke 2006, 1:97-99.
• [27]Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, Mozaffar T, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN, Combination Drug Selection Trial Study Group: A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008, 9:212-222.
• [28]Lewitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM: Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008, 63:295-302.
• [29]Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, Orito K, Egashira N, Iwasaki K, Fujiwara M: Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 2008, 39:951-958.
• [30]Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM: Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009, 46:94-102.
• [31]Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW: Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010, 10:91. BioMed Central Full Text
• [32]Kriz J, Nguyen MD, Julien JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002, 10:268-278.
• [33]Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP: Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004, 19:337-342.
• [34]Le Couteur A, Lord C, Rutter M: Autism Diagnostic Interview-Revised (ADI-R). Los Angeles: Western Psychological Services; 2003.
• [35]Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M: The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000, 30:205-223.
• [36]Sparrow SS, Cichetti D, Balla D: Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service; 2005.
• [37]Luyster R, Richler J, Risi S, Hsu WL, Dawson G, Bernier R, Dunn M, Hepburn S, Hyman SL, McMahon WM, Goudie-Nice J, Minshew N, Rogers S, Sigman M, Spence MA, Goldberg WA, Tager-Flusberg H, Volkmar FR, Lord C: Early regression in social communication in autism spectrum disorders: a CPEA Study. Dev Neuropsychol 2005, 27:311-336.
• [38]Mullen E: Infant Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service; 1995.
• [39]Elliott C: Manual for the Differential Ability Scales. San Antonio, TX: Pearson Assessments; 2007.
• [40]Guy W: ECDEU Assessment Manual of Psychopharmacology-Revised. Rockville, MD: Psychopharmacology Research Branch; 1976.
• [41]Hussein MH, Daoud GA, Kakita H, Kato S, Goto T, Kamei M, Goto K, Nobata M, Ozaki Y, Ito T, Fukuda S, Kato I, Suzuki S, Sobajima H, Hara F, Hashimoto T, Togari H: High cerebrospinal fluid antioxidants and interleukin 8 are protective of hypoxic brain damage in newborns. Free Radic Res 2010, 44:422-429.
• [42]Thirumangalakudi L, Yin L, Rao HV, Grammas P: IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. J Alzheimers Dis 2007, 11:305-311.
• [43]Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, Portik-Dobos V, Pettigrew LC, Clark WM, Fagan SC: Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 2011, 42:2633-2635.
• [44]Bekinschtein P, Cammarota M, Izquierdo I, Medina JH: BDNF and memory formation and storage. Neuroscientist 2008, 14:147-156.
• [45]Yang J, Siao CJ, Nagappan G, Marinic T, Jing D, McGrath K, Chen ZY, Mark W, Tessarollo L, Lee FS, Lu B, Hempstead BL: Neuronal release of proBDNF. Nat Neurosci 2009, 12:113-115.
• [46]Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, Tongiorgi E, De Vanna M: Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 2011, 45:273-279.
• [47]Carlino D, De Vanna M, Tongiorgi E: Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist 2012. Epub ahead of print
• [48]Garcia KLP, Yu G, Nicolini C, Michalski B, Garzon DJ, Chiu VS, Tongiorgi E, Szatmari P, Fahnestock M: Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism. J Neuropath Exp Neurol 2012, 71:289-297.
• [49]Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, Elia M, Schneider C, Melmed R, Sacco R, Persico AM, Levitt P: A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006, 103:16834-16839.
• [50]Buie T, Campbell DB, Fuchs GJ III, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H: Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010, 125(Suppl 1):S1-S18.